Evidence map›Paper›PMID 37466821›Full record

SynthesisJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2024

Atrial fibrillation catheter ablation in endurance athletes: systematic review and meta-analysis.

Narut Prasitlumkum, Nithi Tokavanich, Noppachai Siranart, Witina Techasatian, Wisit Cheungpasitporn, Leenhapong Navaravong, Ronpichai Chokesuwattanaskul

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Narut PrasitlumkumDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Nithi TokavanichSparrow Hospital, Michigan State University, Lansing, MI, USA.
Noppachai SiranartFaculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Witina TechasatianDepartment of Internal Medicine, University of Hawaii, Honolulu, HI, USA.
Wisit CheungpasitpornDepartment of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Leenhapong NavaravongDepartment of Electrophysiology, Division of Cardiovascular Medicine, University of Utah, Salt Lake, UT, USA.
Ronpichai ChokesuwattanaskulDivision of Cardiology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. drronpichaic@gmail.com.ORCID http://orcid.org/0000-0002-4463-7447
Mayo Clinic in Arizona · USChulalongkorn University · THSparrow Hospital · USThai Red Cross Society · THUniversity of Hawaii System · USUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtrial fibrillation (AF) management in endurance athletes (EA) is challenging due to the paucity of data, especially on the efficacy and safety of catheter ablation (CA). The hypothesis is that the efficacy and safety of AF CA in EA are comparable to the non-EA.

methodsDatabases from EMBASE, Medline, PubMed, and Cochrane were searched from inception through February 2023. Studies with available information on efficacy and safety profiles were included. Effect estimates from the individual studies were extracted and combined using random effect and generic inverse variance method of DerSimonian and Laird.

resultsNine observational studies with a total of 1129 participants were identified, of whom 51% were EA. Our analysis found that rate of atrial arrhythmia (AA) recurrences following AF CA was not statistically different between EA and non-EA (RR 1.04, I

conclusionsOur meta-analysis suggests that AF CA is as effective and safe in EA as in non-EA. In the future, AF CA should be considered as a first-line therapeutic choice in this patient group.

Indexed as

AthletesAtrial FibrillationCatheter AblationHumansPhysical EnduranceAblationAthleteAtrial fibrillationEnduranceOutcomes

Identifiers

PMID37466821
OpenAlexW4384663181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.